In light of the Covid-19 outbreak, this review brings together historical and current literature
efforts towards the development of antiviral metallodrugs. Classical compounds such as …

This review focuses on light-activated ruthenium anticancer compounds and the factors that
influence which pathway is favored. Photodynamic therapy (PDT) is favored by π expansion …

Lack of selectivity is one of the main issues with currently used chemotherapies, causing
damage not only to altered cells but also to healthy cells. Over the last decades …

One approach to reduce the side effects of chemotherapy in cancer treatment is
photodynamic therapy (PDT), which allows spatiotemporal control of the cytotoxicity. We …

Light‐activated treatments, such as photodynamic therapy (PDT), provide temporal and
spatial control over a specific cytotoxic response by exploiting toxicity differences between …

An increasing number of novel Ru (II) polypyridyl complexes have been successfully applied
as photosensitizers (PSs) for photodynamic therapy (PDT). Despite recent advances in …

Tridentate ligand-coordinated ruthenium (II) polypyridyl complexes with large N–Ru–N bite
angles have been shown to promote ligand field splitting and reduce singlet–triplet state …

Ru (II)-and Cu (I)-based photosensitizers featuring the recently developed biipo ligand (16H-
benzo-[4′, 5′]-isoquinolino-[2′, 1′,: 1, 2]-imidazo-[4, 5-f]-[1, 10]-phenanthrolin-16-one) …

Ru (II)-polypyridyl complexes supported with imidazo [4, 5-f][1, 10] phenanthroline ligand are
of increasing interest as photosensitizers in different research areas. A combination of rich …

Ruthenium (II) complexes containing diimine ligands have contributed to the development of
agents for photoactivated chemotherapy. Several approaches have been used to obtain …